COX-2 Woes May Provide Respite For Drugs Frequently Targeted In Litigation
This article was originally published in The Pink Sheet Daily
Executive Summary
The uproar over COX-2 inhibitors may provide an upside for other drugs that are longstanding litigation targets, such as Lilly's atypical antipsychotic Zyprexa